These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 28298269)

  • 1. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.
    Mokhtari Z; Gibson DL; Hekmatdoost A
    Adv Nutr; 2017 Mar; 8(2):240-252. PubMed ID: 28298269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
    Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
    Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease.
    Shama S; Liu W
    Dig Dis Sci; 2020 Mar; 65(3):906-910. PubMed ID: 32036510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
    Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
    Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
    Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gut microbiota and nonalcoholic steatohepatitis].
    Kessoku T; Imajo K; Kobayashi T; Honda Y; Ogawa Y; Yoneda M; Saito S; Nakajima A
    Nihon Yakurigaku Zasshi; 2018; 152(4):187-193. PubMed ID: 30298840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).
    Safari Z; Gérard P
    Cell Mol Life Sci; 2019 Apr; 76(8):1541-1558. PubMed ID: 30683985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota and non-alcoholic fatty liver disease.
    Gkolfakis P; Dimitriadis G; Triantafyllou K
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between PPARs and gut microbiota in NAFLD.
    Wu L; Li J; Feng J; Ji J; Yu Q; Li Y; Zheng Y; Dai W; Wu J; Guo C
    Biomed Pharmacother; 2021 Apr; 136():111255. PubMed ID: 33485064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
    Aron-Wisnewsky J; Warmbrunn MV; Nieuwdorp M; Clément K
    Gastroenterology; 2020 May; 158(7):1881-1898. PubMed ID: 32044317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiome and nonalcoholic fatty liver disease.
    Wu MY; Fan JG
    Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):444-451. PubMed ID: 37308360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.